Zacks Investment Research upgraded shares of Sartorius (OTCMKTS:SARTF) from a hold rating to a buy rating in a report issued on Wednesday morning, Zacks.com reports. They currently have $192.00 price objective on the stock.

According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “

Separately, DZ Bank restated a sell rating on shares of Sartorius in a research note on Friday, July 19th.

OTCMKTS:SARTF opened at $192.10 on Wednesday. The stock has a fifty day simple moving average of $172.27. The firm has a market capitalization of $6.57 billion, a P/E ratio of 63.61 and a beta of -0.12. The company has a current ratio of 1.37, a quick ratio of 0.77 and a debt-to-equity ratio of 0.93. Sartorius has a 52 week low of $109.50 and a 52 week high of $192.10.

Sartorius Company Profile

There is no company description available for Sartorius AG.

Featured Article: 12b-1 Fees

Get a free copy of the Zacks research report on Sartorius (SARTF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.